Zogenix's FINTEPLA has been granted orphan drug status in Japan. FINTEPLA is used in the U.S. and Europe to treat seizures caused by Dravet syndrome, a rare form of epilepsy. In Japan, the company plans to file a J-NDA application later this year. If approved, the drug will be distributed in the country under an exclusive distribution agreement with Nippon Shinyaku.